FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1564-1573 October 13, 2005 Number 15 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Cullen, M. R. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background We investigated the presence of osteopontin in pleural mesothelioma and determined serum osteopontin levels in three populations: subjects without cancer who were exposed to asbestos, subjects without cancer who were not exposed to asbestos, and patients with pleural mesothelioma who were exposed to asbestos.

Methods A group of 69 subjects with asbestos-related nonmalignant pulmonary disease were compared with 45 subjects without exposure to asbestos and 76 patients with surgically staged pleural mesothelioma. Tumor tissue was examined for osteopontin by immunohistochemical analysis, and serum osteopontin levels were measured by an enzyme-linked immunosorbent assay.

Results There were no significant differences in mean (±SE) serum osteopontin levels between age-matched subjects with exposure to asbestos and subjects without exposure to asbestos (30±3 ng per milliliter and 20±4 ng per milliliter, respectively; P=0.06). In the group with exposure to asbestos, elevated serum osteopontin levels were associated with pulmonary plaques and fibrosis (56±13 ng per milliliter) but not with normal radiographic findings (21±5 ng per milliliter), plaques alone (23±3 ng per milliliter), or fibrosis alone (32±7 ng per milliliter) (P=0.004). Serum osteopontin levels were significantly higher in the group with pleural mesothelioma than in the group with exposure to asbestos (133±10 ng per milliliter vs. 30±3 ng per milliliter, P<0.001). Immunohistochemical analysis revealed osteopontin staining of the tumor cells in 36 of 38 samples of pleural mesothelioma. An analysis of serum osteopontin levels comparing the receiver-operating-characteristic curve in the group exposed to asbestos with that of the group with mesothelioma had a sensitivity of 77.6 percent and a specificity of 85.5 percent at a cutoff value of 48.3 ng of osteopontin per milliliter. Subgroup analysis comparing patients with stage I mesothelioma with subjects with exposure to asbestos revealed a sensitivity of 84.6 percent and a specificity of 88.4 percent at a cutoff value of 62.4 ng of osteopontin per milliliter.

Conclusions Serum osteopontin levels can be used to distinguish persons with exposure to asbestos who do not have cancer from those with exposure to asbestos who have pleural mesothelioma.

Source Information

From the Departments of Surgery (H.I.P., N.T., A.W.), Pathology (F.L.), Medicine (M.H.), and Computer Science (Z.L.) and the Center for Molecular Genetics (D.L.), Wayne State University, Karmanos Cancer Institute, John A. Dingell Veterans Hospital, Detroit; the Department of Pathology, Cardinal Bernardin Cancer Center, Loyola University, Maywood, Ill. (M.C.); and the Laboratory of Tumor Metastasis and Angiogenesis, Van Andel Research Institute, Grand Rapids, Mich. (C.W.).

Address reprint requests to Dr. Pass at the NYU School of Medicine, Department of Cardiothoracic Surgery, 530 1st Ave., Suite 9V, New York, NY 10016, or at harvey.pass{at}med.nyu.edu.

Full Text of this Article

Related Letters:

Asbestos Exposure and Serum Osteopontin
O'Regan A. W., Serlin D., Berman J. S., Hiraki A., Aoe K., Ueoka H., Pass H. I., Carbone M., Wali A.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:304-305, Jan 19, 2006. Correspondence

This article has been cited by other articles:

• Ray, M., Kindler, H. L. (2009). Malignant Pleural Mesothelioma: An Update on Biomarkers and Treatment. Chest 136: 888-896 [Abstract] [Full Text]  
• Krug, L. M., Pass, H. I., Rusch, V. W., Kindler, H. L., Sugarbaker, D. J., Rosenzweig, K. E., Flores, R., Friedberg, J. S., Pisters, K., Monberg, M., Obasaju, C. K., Vogelzang, N. J. (2009). Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma. JCO 27: 3007-3013 [Abstract] [Full Text]  
• OHASHI, R., TAJIMA, K., TAKAHASHI, F., CUI, R., GU, T., SHIMIZU, K., NISHIO, K., FUKUOKA, K., NAKANO, T., TAKAHASHI, K. (2009). Osteopontin Modulates Malignant Pleural Mesothelioma Cell Functions In Vitro. Anticancer Res 29: 2205-2214 [Abstract] [Full Text]  
• Grigoriu, B. D., Chahine, B., Vachani, A., Gey, T., Conti, M., Sterman, D. H., Marchandise, G., Porte, H., Albelda, S. M., Scherpereel, A. (2009). Kinetics of Soluble Mesothelin in Patients with Malignant Pleural Mesothelioma during Treatment. Am. J. Respir. Crit. Care Med. 179: 950-954 [Abstract] [Full Text]  
• Tsao, A. S., Wistuba, I., Roth, J. A., Kindler, H. L. (2009). Malignant Pleural Mesothelioma. JCO 27: 2081-2090 [Abstract] [Full Text]  
• Ivanova, A. V., Goparaju, C. M.V., Ivanov, S. V., Nonaka, D., Cruz, C., Beck, A., Lonardo, F., Wali, A., Pass, H. I. (2009). Protumorigenic Role of HAPLN1 and Its IgV Domain in Malignant Pleural Mesothelioma. Clin. Cancer Res. 15: 2602-2611 [Abstract] [Full Text]  
• Park, E.-K., Thomas, P. S., Johnson, A. R., Yates, D. H. (2009). Osteopontin Levels in an Asbestos-Exposed Population. Clin. Cancer Res. 15: 1362-1366 [Abstract] [Full Text]  
• Hui, E. P., Sung, F. L., Yu, B. K.H., Wong, C. S.C., Ma, B. B.Y., Lin, X., Chan, A., Wong, W.-l., Chan, A. T.C. (2008). Plasma Osteopontin, Hypoxia, and Response to Radiotherapy in Nasopharyngeal Cancer. Clin. Cancer Res. 14: 7080-7087 [Abstract] [Full Text]  
• Park, E.-K., Sandrini, A., Yates, D. H., Creaney, J., Robinson, B. W., Thomas, P. S., Johnson, A. R. (2008). Soluble Mesothelin-related Protein in an Asbestos-exposed Population: The Dust Diseases Board Cohort Study. Am. J. Respir. Crit. Care Med. 178: 832-837 [Abstract] [Full Text]  
• Mack, P. C., Redman, M. W., Chansky, K., Williamson, S. K., Farneth, N. C., Lara, P. N. Jr, Franklin, W. A., Le, Q.-T., Crowley, J. J., Gandara, D. R. (2008). Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non-Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003. JCO 26: 4771-4776 [Abstract] [Full Text]  
• Rosenberg, M., Zugck, C., Nelles, M., Juenger, C., Frank, D., Remppis, A., Giannitsis, E., Katus, H. A., Frey, N. (2008). Osteopontin, a New Prognostic Biomarker in Patients With Chronic Heart Failure. Circ Heart Fail 1: 43-49 [Abstract] [Full Text]  
• Nguyen, D., Lee, S.-J., Libby, E., Verschraegen, C. (2008). Rate of Thromboembolic Events in Mesothelioma. Ann. Thorac. Surg. 85: 1032-1038 [Abstract] [Full Text]  
• Shiomi, K., Hagiwara, Y., Sonoue, K., Segawa, T., Miyashita, K., Maeda, M., Izumi, H., Masuda, K., Hirabayashi, M., Moroboshi, T., Yoshiyama, T., Ishida, A., Natori, Y., Inoue, A., Kobayashi, M., Sakao, Y., Miyamoto, H., Takahashi, K., Hino, O. (2008). Sensitive and Specific New Enzyme-Linked Immunosorbent Assay for N-ERC/Mesothelin Increases its Potential as a Useful Serum Tumor Marker for Mesothelioma. Clin. Cancer Res. 14: 1431-1437 [Abstract] [Full Text]  
• Heffner, J. E., Klein, J. S. (2008). Recent Advances in the Diagnosis and Management of Malignant Pleural Effusions. Mayo Clin Proc. 83: 235-250 [Abstract] [Full Text]  
• Bertino, P., Piccardi, F., Porta, C., Favoni, R., Cilli, M., Mutti, L., Gaudino, G. (2008). Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts. Clin. Cancer Res. 14: 541-548 [Abstract] [Full Text]  
• Pass, H. I., Wali, A., Tang, N., Ivanova, A., Ivanov, S., Harbut, M., Carbone, M., Allard, J. (2008). Soluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural Effusions. Ann. Thorac. Surg. 85: 265-272 [Abstract] [Full Text]  
• British Thoracic Society Standards of Care Committ, (2007). BTS statement on malignant mesothelioma in the UK, 2007. Thorax 62: ii1-ii19 [Full Text]  
• Hardie, W. D., Korfhagen, T. R., Sartor, M. A., Prestridge, A., Medvedovic, M., Le Cras, T. D., Ikegami, M., Wesselkamper, S. C., Davidson, C., Dietsch, M., Nichols, W., Whitsett, J. A., Leikauf, G. D. (2007). Genomic Profile of Matrix and Vasculature Remodeling in TGF-{alpha} Induced Pulmonary Fibrosis. Am. J. Respir. Cell Mol. Bio. 37: 309-321 [Abstract] [Full Text]  
• Sterman, D. H., Recio, A., Carroll, R. G., Gillespie, C. T., Haas, A., Vachani, A., Kapoor, V., Sun, J., Hodinka, R., Brown, J. L., Corbley, M. J., Parr, M., Ho, M., Pastan, I., Machuzak, M., Benedict, W., Zhang, X.-q., Lord, E. M., Litzky, L. A., Heitjan, D. F., June, C. H., Kaiser, L. R., Vonderheide, R. H., Albelda, S. M. (2007). A Phase I Clinical Trial of Single-Dose Intrapleural IFN-{beta} Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses. Clin. Cancer Res. 13: 4456-4466 [Abstract] [Full Text]  
• Suzuki, M., Mose, E., Galloy, C., Tarin, D. (2007). Osteopontin Gene Expression Determines Spontaneous Metastatic Performance of Orthotopic Human Breast Cancer Xenografts. Am. J. Pathol. 171: 682-692 [Abstract] [Full Text]  
• Creaney, J., Yeoman, D., Naumoff, L. K, Hof, M., Segal, A., Musk, A. W., De Klerk, N., Horick, N., Skates, S. J, Robinson, B. W S (2007). Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 62: 569-576 [Abstract] [Full Text]  
• Grigoriu, B.-D., Scherpereel, A., Devos, P., Chahine, B., Letourneux, M., Lebailly, P., Gregoire, M., Porte, H., Copin, M.-C., Lassalle, P. (2007). Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment. Clin. Cancer Res. 13: 2928-2935 [Abstract] [Full Text]  
• Alonso, S. R., Tracey, L., Ortiz, P., Perez-Gomez, B., Palacios, J., Pollan, M., Linares, J., Serrano, S., Saez-Castillo, A. I., Sanchez, L., Pajares, R., Sanchez-Aguilera, A., Artiga, M. J., Piris, M. A., Rodriguez-Peralto, J. L. (2007). A High-Throughput Study in Melanoma Identifies Epithelial-Mesenchymal Transition as a Major Determinant of Metastasis. Cancer Res. 67: 3450-3460 [Abstract] [Full Text]  
• Beyer, H. L., Geschwindt, R. D., Glover, C. L., Tran, L., Hellstrom, I., Hellstrom, K.-E., Miller, M. C., Verch, T., Allard, W. J., Pass, H. I., Sardesai, N. Y. (2007). MESOMARKTM: A Potential Test for Malignant Pleural Mesothelioma. Clin. Chem. 53: 666-672 [Abstract] [Full Text]  
• Lee, J.-L., Wang, M.-J., Sudhir, P.-R., Chen, G.-D., Chi, C.-W., Chen, J.-Y. (2007). Osteopontin Promotes Integrin Activation through Outside-In and Inside-Out Mechanisms: OPN-CD44V Interaction Enhances Survival in Gastrointestinal Cancer Cells. Cancer Res. 67: 2089-2097 [Abstract] [Full Text]  
• Scherpereel, A., Grigoriu, B., Conti, M., Gey, T., Gregoire, M., Copin, M.-C., Devos, P., Chahine, B., Porte, H., Lassalle, P. (2006). Soluble Mesothelin-related Peptides in the Diagnosis of Malignant Pleural Mesothelioma. Am. J. Respir. Crit. Care Med. 173: 1155-1160 [Abstract] [Full Text]  
• O'Regan, A. W., Serlin, D., Berman, J. S., Hiraki, A., Aoe, K., Ueoka, H., Pass, H. I., Carbone, M., Wali, A. (2006). Asbestos Exposure and Serum Osteopontin. NEJM 354: 304-305 [Full Text]  
• Hui, C K (2006). Using serum osteopontin to help identify pleural mesothelioma. Thorax 61: 22-22 [Full Text]  
• Tonks, A. (2005). What's new in the other general journals. BMJ 331: 927-928 [Full Text]  
• Cullen, M. R. (2005). Serum osteopontin levels--is it time to screen asbestos-exposed workers for pleural mesothelioma?. NEJM 353: 1617-1618 [Full Text]